{"id":"https://openalex.org/W2161531371","doi":"https://doi.org/10.1200/jco.2006.07.4658","title":"What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials","display_name":"What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials","alternate_titles":[],"publication_year":2006,"publication_date":"2006-08-30","ids":{"openalex":"https://openalex.org/W2161531371","doi":"https://doi.org/10.1200/jco.2006.07.4658","mag":"2161531371","pmid":"https://pubmed.ncbi.nlm.nih.gov/16943522"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.07.4658","doi":"https://doi.org/10.1200/jco.2006.07.4658","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.07.4658","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2161531371"],"child_works_count":0,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113962365","display_name":"Alex A. Adjei","orcid":"https://orcid.org/0000-0002-8039-6556","observed_orcids":["https://orcid.org/0000-0002-8039-6556"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4390039279","display_name":"Mayo Clinic Comprehensive Cancer Center (Minnesota)","ror":"https://ror.org/012wxv498","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alex A. Adjei","raw_affiliation_strings":["Department of Oncology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5113962365"],"corresponding_institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":104,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"25","first_page":"4054","last_page":"4055"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enzastaurin","display_name":"enzastaurin","score":0.9079999923706055},{"id":"https://openalex.org/keywords/target-plasma-concentration","display_name":"target plasma concentration","score":0.5860000252723694},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.7310000061988831},{"id":"https://openalex.org/keywords/inter-individual-variability","display_name":"interindividual variability","score":0.7310000061988831},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.4399999976158142},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6790000200271606},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.5870000123977661},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.6079999804496765},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.5230000019073486},{"id":"https://openalex.org/keywords/small-molecule-kinase-inhibitors","display_name":"small-molecule kinase inhibitors","score":0.5870000123977661},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.35100001096725464}],"concepts":[{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.7214609980583191},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6614367365837097},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6222378611564636},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6212862730026245},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5850168466567993},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.4799497425556183},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.47000131011009216},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4636576771736145},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.4553426504135132},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.4358023405075073},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.41291964054107666},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3245541453361511},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26349833607673645}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011493","descriptor_name":"Protein Kinase C","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D064546","descriptor_name":"Protein Kinase C beta","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2006.07.4658","doi":"https://doi.org/10.1200/jco.2006.07.4658","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.07.4658","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:16943522","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16943522","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Comment"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W31750938","https://openalex.org/W61400814","https://openalex.org/W2074470232","https://openalex.org/W2128373232","https://openalex.org/W2156509877","https://openalex.org/W2172187886","https://openalex.org/W2416957871"],"related_works":["https://openalex.org/W4236759481","https://openalex.org/W2091666474","https://openalex.org/W4366396718","https://openalex.org/W2946639201","https://openalex.org/W2128373232","https://openalex.org/W2494787454","https://openalex.org/W3120325488","https://openalex.org/W2325726156","https://openalex.org/W2506115417"],"abstract_inverted_index":{"Phase":[0],"I":[1,143,177,325,867,871],"trials":[2],"aim":[3],"to":[4,27,65,96,134,206,237,276,297,350,368,373,599,664,728,816],"determine":[5],"the":[6,28,40,45,52,54,56,58,66,175,197,210,216,231,240,258,261,267,313,333,383,393,401,425,432,442,477,511,527,535,548,555,559,568,576,646,671,688,699,712,722,736,774,810,840,848],"optimal":[7,149,647,694,849],"dose":[8,24,30,69,155,345,352,411,529,630,696,733,761,821,850],"of":[9,36,47,60,100,147,179,199,233,269,312,315,327,332,353,385,403,428,438,445,463,530,538,551,558,631,711,762,776,794,812,843,859],"a":[10,77,86,97,137,154,159,164,200,322,329,351,375,405,420,456,620,629,666,758,763,820],"new":[11,98],"compound":[12],"for":[13,88,174,225,272,418,488,506,836],"subsequent":[14],"testing":[15],"in":[16,91,132,141,219,247,283,306,356,410,452,483,491,496,547,585,601,634,690,701,724,744,748,856],"phase":[17,142,176,324,395,635,759],"II":[18,396,636,760],"trials.":[19,144],"With":[20,828],"cytotoxic":[21,73],"agents,":[22,614,773,847],"this":[23,310,357,471,589,644,829],"typically":[25,449],"corresponds":[26],"highest":[29],"associated":[31],"with":[32,125,239,300,364,470,611,673,765],"an":[33,148,638,659,831],"acceptable":[34],"level":[35],"toxicity,":[37,123],"based":[38,407,423],"on":[39,424],"underlying":[41],"assumption":[42],"stemming":[43],"from":[44,303,482,771],"work":[46],"Skipper":[48],"et":[49,319],"al":[50,320],"that":[51,103,156,209,434,448,526,582,720,738,805,822],"higher":[53],"dose,":[55,151],"greater":[57],"likelihood":[59],"drug":[61,160,217,235,248,262,292,429,447,461,513,595,603,672,691,713,746,764],"efficacy.":[62,89],"In":[63,196,309,839],"addition":[64],"relationship":[67],"between":[68],"and":[70,106,109,117,172,250,371,379,675,715],"antitumor":[71],"response,":[72],"agents":[74,102,113,788],"also":[75],"exhibit":[76],"dose-toxicity":[78],"relationship.":[79],"Thus,":[80,553,809],"dose-related":[81],"toxicity":[82,135],"is":[83,168,187,255,431,493,580,645,783],"regarded":[84],"as":[85,136,153,170,242,244,257,264,266,392,592,594,680,819],"surrogate":[87,138],"Advances":[90],"molecular":[92],"biology":[93],"have":[94],"led":[95],"generation":[99],"anticancer":[101,613],"inhibit":[104,215,534,698],"aberrant":[105],"cancer-specific":[107],"proliferative":[108],"antiapoptotic":[110],"pathways.":[111],"These":[112,605],"may":[114,118,286,516,686,851],"be":[115,194,207,277,298,416,518,642,662,708,718,741,817,824,834,852],"cytostatic":[116],"produce":[119],"relatively":[120,181],"minimal":[121,766],"organ":[122,768],"compared":[124],"standard":[126],"cytotoxics.":[127],"This":[128,185,222,398],"has":[129,205,275,778],"fueled":[130],"interest":[131],"alternatives":[133],"end":[139,202,259,408],"point":[140,409],"The":[145,413,468,486,731],"concept":[146,811],"biologic":[150,695],"defined":[152,348,481,853],"reliably":[157],"inhibits":[158,435],"target":[161,165,211,218,253,281,304,421,457,512,528,569,577,700,723],"or":[162,566],"achieves":[163],"plasma":[166,226,386,549,563,602],"concentration,":[167,570],"seen":[169],"desirable":[171],"appropriate":[173,188],"study":[178,326,399],"mechanismbased,":[180],"nontoxic":[182],"novel":[183],"agents.":[184],"idea":[186],"if":[189,624,785],"certain":[190],"inherent":[191],"problems":[192,469],"can":[193,214,533,597,823,833],"resolved.":[195],"case":[198,842],"pharmacokinetic":[201],"point,":[203,260],"it":[204,782],"shown":[208],"concentration":[212,366,422,433,462,514],"chosen":[213,256,515],"patient":[220,540,702],"tumors.":[221,541,703],"requires":[223],"accounting":[224],"protein":[227,336],"binding,":[228],"which":[229,430,615,777],"determines":[230],"amount":[232],"free":[234,426],"available":[236],"interact":[238],"target,":[241,263,714],"well":[243,265,593],"interindividual":[245],"variations":[246,600,743],"absorption":[249],"metabolism.":[251],"When":[252],"modulation":[254],"magnitude":[268],"inhibition":[270,282],"necessary":[271],"clinical":[273],"benefit,":[274],"known.":[278],"Finally,":[279],"although":[280],"normal":[284,497],"tissue":[285,498],"provide":[287],"important":[288],"supplementary":[289],"information,":[290],"critical":[291],"development":[293,775],"decisions":[294],"will":[295,740,797,814],"need":[296,815],"made":[299,663],"information":[301],"gleaned":[302],"suppression":[305],"tumor":[307],"samples.":[308],"issue":[311],"Journal":[314],"Clinical":[316],"Oncology,":[317],"Carducci":[318],"describe":[321],"multicenter":[323],"enzastaurin,":[328],"small-molecule":[330,792],"inhibitor":[331],"serine/threonine":[334],"kinase":[335,337,536],"C":[338],"beta":[339],"(PKC).":[340],"No":[341],"classical":[342,667],"toxicity-based":[343],"maximum-tolerated":[344],"(MTD)":[346],"was":[347,390,466],"up":[349,367],"700":[354,380],"mg/d":[355,633],"47-patient":[358],"study.":[359],"Total":[360],"enzastaurin":[361,625],"exposure":[362],"increased":[363],"increasing":[365],"240":[369],"mg":[370,389],"appeared":[372],"reach":[374],"plateau":[376,689],"at":[377,554,565,619,628,802],"525":[378,388,632,657],"mg.":[381],"On":[382],"basis":[384],"exposures,":[387],"selected":[391,732],"recommended":[394],"dose.":[397,648],"illustrates":[400],"complexities":[402],"using":[404],"pharmacokinetically":[406],"selection.":[412],"investigators":[414],"should":[415,697,707,717,734],"commended":[417],"selecting":[419],"fraction":[427],"90%":[436],"(IC90)":[437],"PKCactivity,":[439],"rather":[440],"than":[441],"IC50":[443],"values":[444,479],"total":[446,460],"are":[450,474,504,522,609,616],"used":[451],"such":[453,787],"studies.":[454],"Thus":[455],"mean":[458],"steady-state":[459,650,745],"1,400":[464,531],"nmol/L":[465,532],"chosen.":[467],"approach,":[472],"however,":[473],"three-fold.":[475],"First,":[476],"IC90":[478,487],"were":[480,626],"vitro":[484],"analysis.":[485],"inhibiting":[489],"PKC":[490],"vivo":[492,503],"unknown.":[494],"Data":[495],"(peripheral-blood":[499],"mononuclear":[500],"cells)":[501],"ex":[502],"presented":[505],"only":[507],"four":[508],"patients.":[509,749],"Therefore,":[510],"not":[517],"optimal.":[519],"Second,":[520],"there":[521,706,716,739],"no":[523],"data":[524],"indicating":[525],"activity":[537],"PKCin":[539],"Third,":[542],"substantial":[543],"interpatient":[544],"variability":[545],"exist":[546],"profiles":[550],"enzastaurin.":[552],"MTD,":[556],"seven":[557],"12":[560],"patients":[561],"had":[562,573],"levels":[564,574,747],"above":[567,656],"whereas":[571],"five":[572],"below":[575],"concentration.":[578],"It":[579],"known":[581],"genetic":[583],"polymorphisms":[584],"drug-metabolizing":[586],"enzymes":[587],"(in":[588],"case,":[590],"CYP3A4),":[591],"transporters,":[596],"lead":[598],"levels.":[604],"polymorphic":[606],"enzyme":[607],"variants":[608],"crucial":[610],"oral":[612],"usually":[617],"dosed":[618],"flat":[621],"rate.":[622],"Clearly,":[623],"ineffective":[627],"studies,":[637],"unanswered":[639],"question":[640],"would":[641],"whether":[643],"Although":[649],"concentrations":[651],"argued":[652],"against":[653],"escalating":[654],"doses":[655,804],"mg/d,":[658],"attempt":[660],"could":[661],"define":[665],"MTD":[668,813,832],"by":[669,854],"administering":[670],"food":[674],"exploring":[676],"split":[677],"dosing":[678],"(such":[679],"twice":[681],"daily":[682],"dosing).":[683],"Both":[684],"approaches":[685],"overcome":[687],"absorption.":[692],"An":[693],"Most":[704,791],"importantly,":[705],"absolute":[709],"certainty":[710],"evidence":[719],"modulating":[721],"tumors":[725],"consistently":[726],"leads":[727],"growth":[729],"inhibition.":[730],"incorporate":[735],"fact":[737],"wide":[742],"Having":[750],"outlined":[751],"these":[752],"issues,":[753],"how":[754],"does":[755],"one":[756],"select":[757],"dose-dependent":[767],"toxicities?":[769],"Apart":[770],"immunotherapeutic":[772],"been":[779],"reviewed":[780],"recently,":[781],"debatable":[784],"many":[786],"currently":[789],"exist.":[790],"inhibitors":[793],"cellular":[795],"proteins":[796],"demonstrate":[798],"chronic":[799],"low-grade":[800],"toxicities":[801],"high":[803],"preclude":[806],"continuous":[807],"dosing.":[808],"redefined":[818],"safely":[825],"administered":[826],"chronically.":[827],"definition,":[830],"established":[835],"most":[837],"drugs.":[838],"rare":[841],"truly":[844],"minimally":[845],"toxic":[846],"saturation":[855],"absorption,":[857],"quantity":[858],"tablets":[860],"JOURNAL":[861],"OF":[862],"CLINICAL":[863],"ONCOLOGY":[864],"E":[865],"D":[866],"T":[868],"O":[869],"R":[870],"A":[872],"L":[873],"VOLUME":[874],"24":[875],"NUMBER":[876],"25":[877],"SEPTEMBER":[878],"1":[879],"2006":[880]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2161531371","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
